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(EQ-5D-5L) value set for Poland on the basis of the crosswalk method-
ology developed by the EuroQol Group. Methods: On the basis of data
from 3691 respondents from six European countries, the EuroQol
Group has developed a method of obtaining interim value sets for
the EQ-5D-5L by means of mapping to the available three-level
EuroQol ﬁve-dimensional (EQ-5D-3L) value sets (“crosswalk” method-
ology). A signiﬁcant part of the data in this study came from Polish
respondents (n ¼ 972; 26.3%). Poland is the ﬁrst Central European
country with EQ-5D-3L time trade-off–based social value set pub-
lished. To obtain an interim EQ-5D-5L value set, we applied the
crosswalk methodology to the Polish EQ-5D-3L value set. Results:
Estimated Polish values for 3125 EQ-5D-5L health states are presented.
Both EQ-5D-5L and EQ-5D-3L value sets have the same range (from
0.523 to 1.000), but different means (0.448 vs. 0.380) and medians
(0.483 vs. 0.403), respectively. Proportionately fewer states worse thanee front matter Copyright & 2014, International S
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Warsaw, Poland.dead were observed in the EQ-5D-5L (5.4%) value set than in the EQ-
5D-3L (13.2%) value set. Conclusions: The crosswalk-based value set is
available for use in EQ-5D-5L studies in Poland to calculate health state
utilities. It should be considered an interim value set until values based
on preferences elicited directly from a sample representative of the
Polish general population become available. This study helps users of
the crosswalk algorithm understand the properties of the EQ-5D-5L
values generated using this method, in comparison to EQ-5D-3L values
obtained with the Polish time trade-off value set. It is likely that similar
results would be observed for values sets in other countries because the
same crosswalk methodology applies across all countries.
Keywords: EQ-5D, 5-level, models, statistical, quality of life,
questionnaires, nonparametric.
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The EuroQol ﬁve-dimensional (EQ-5D) is the most commonly
used preference-based quality-of-life measure deriving health
state utilities for use in cost-utility analyses [1]. A new ﬁve-level
version of the EQ-5D (ofﬁcial name EQ-5D-5L) has been recently
developed by the EuroQol Group [2,3]. The EQ-5D-5L appears to be
a valid extension of the three-level system. Evidence suggests
that it improves the measurement properties of the three-level
EuroQol ﬁve-dimensional (EQ-5D-3L) by reducing the ceiling and
improving discriminatory power, and establishing convergent
and known-groups validity [4].
One of the advantages of the EQ-5D is the availability of
country-speciﬁc value sets. These country-speciﬁc value sets,
obtained from the general population, enable the derivation of
index-based utility scores by applying weights to the dimensions
and levels described by the EQ-5D health state classiﬁer system
when completed by respondents. EQ-5D-5L value sets based onpreferences directly elicited from representative general popula-
tion samples are under development [5–11].
In the meantime, an interim scoring method for the EQ-5D-5L
was published that allows EQ-5D-5L values to be derived from
any existing EQ-5D-3L value set [12]. Interim values are available
for 10 countries (Denmark, France, Germany, Japan, The Nether-
lands, Spain, Thailand, the United Kingdom, the United States,
and Zimbabwe), but none for Central or Eastern European
countries [13].
Poland was the ﬁrst Central European country to have a EQ-
5D-3L time trade-off (TTO)-based social values set [14]. The Polish
value set is recommended by the Agency for Health Technology
Assessment in Poland guidelines [15], and it is used in health
technology assessment dossiers submitted for reimbursement
purposes [16] and other clinical studies in Poland [17,18].
In the present study, we aimed to estimate an interim EQ-5D-
5L value set for Poland on the basis of the crosswalk methodology
developed by the EuroQol Group and to compare and contrastociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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on the EQ-5D-3L.Methods
The EuroQol Five-Dimensional
The EQ-5D is a standardized measure of health status developed
by the EuroQol Group to provide a simple, generic measure of
health for clinical and economic analyses and population health
surveys [19]. It is cognitively undemanding and designed primar-
ily for self-completion in paper and pencil version, but it can also
be used in face-to-face interviews, by telephone, asking the
proxy, or in electronic versions (personal digital assistant, tablet,
and worldwide web) [20].
Both the EQ-5D-3L and the EQ-5D-5L consist of two pages: the
EQ-5D descriptive system (page 2) and the EQ visual analog scale
(EQ VAS) (page 3). The EQ-5D-5L descriptive system comprises the
same ﬁve dimensions as the EQ-5D-3L (mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression), but it has
ﬁve levels of severity (no problems, slight problems, moderate
problems, severe problems, and extreme problems) compared
with three levels (no problems, some problems, and extreme
problems) in the EQ-5D-3L. The respondent is asked to indicate
his or her health state by ticking (or placing a cross) in the box
against the most appropriate statement in each of the ﬁve
dimensions. The responses for the ﬁve dimensions can be
combined in a ﬁve-digit number describing the respondent’s
health state (from “11111,” meaning no problems at all, to
“55555,” meaning extreme problems in all the ﬁve dimensions)
[3]. A total of 243 and 3125 possible health states are deﬁned in
this way in the EQ-5D-3L and the EQ-5D-5L, respectively. EQ-5D
health states, deﬁned by the EQ-5D descriptive system, may be
converted into a single summary index by applying a formula
that essentially attaches values (also called weights) to each of
the levels in each dimension. Information in this format is useful,
especially, in cost-utility analyses. Value sets for all health states
deﬁned by the EQ-5D-3L descriptive system have been derived in
several countries using the EQ VAS or TTO valuation techniques
[14]. The EQ VAS records the respondent’s self-rated health on a
20-cm long, vertical, visual analog scale with end points labeled
“the best health you can imagine” and “the worst health you can
imagine.” This derives information about subjective perception of
health, measured quantitatively by the individual respondents.
The EQ-5D-3L and the EQ-5D-5L have now been translated into
more than 170 and 110 languages, respectively.
Crosswalk Study
The objective of the Crosswalk study was to develop values sets
for the EQ-5D-5L by means of a mapping (“crosswalk”) to the
currently available EQ-5D-3L value sets [12]. A total of 3691
respondents from six European countries (Denmark, England,
Italy, The Netherlands, Poland, and Scotland) were included in
the study. Participants had a range of different conditions
(arthritis, diabetes, injuries, rheumatoid arthritis, liver disease,
personality disorders, depression, cardiovascular disease, chronic
obstructive pulmonary disease, others) and different levels of
severity of reported problems. Respondents completed both the
EQ-5D-3L and the EQ-5D-5L descriptive systems at the same time.
Crosswalk Methodology
Four mapping models to generate value sets for the EQ-5D-5L
were explored: linear regression, nonparametric, ordered logistic
regression, and item-response theory. The nonparametric model
was chosen as a preferred approach for its simplicity and goodpredictive power [12]. For each health state described by the EQ-
5D-5L system (n ¼ 3125), the probability of reporting each of the
243 EQ-5D-3L health states was estimated (a 3125  243 matrix of
transition probabilities) [13]. The EQ-5D-5L index value is calcu-
lated by multiplying the 243 transition probabilities by their
corresponding EQ-5D-3L index values, and subsequently sum-
ming them up.
Polish EQ-5D-3L Value Set
Polish EQ-5D-3L valuation study used the modiﬁed Measurement
and Value of Health protocol (from the Measurement and Value
of Health study) [21]. Each of the 305 respondents from the
general population valued 23 health states using the TTO
method. Modeling, performed on more than 6700 valuations,
resulted in the ﬁnal choice of the classical random-effects model,
without any interaction variables. Polish EQ-5D-3L value set
characterizes with the lowest value of 0.523 for the 33333 health
state and about 13% of states valued worse than dead. Interna-
tional comparisons showed that Polish values differ considerably
from those elicited in Western European countries [14].
To obtain a Polish interim EQ-5D-5L value set, we applied the
crosswalk methodology developed by the EuroQol Group [12] to
the Polish EQ-5D-3L TTO-based value set [14]. We examined the
differences between values obtained using each approach by
comparing the mean 3L and 5L value scores and the distribution
of values across all Polish respondents in the crosswalk study
and within the value set. We also estimated the proportion of
states with values less than 0 (worse than dead). The statistical
analysis was conducted using the StatsDirect 2.7.8 software
(StatsDirect Ltd, Altrincham, England).Results
Estimated Polish values for 3125 EQ-5D-5L health states are
presented in Appendix 1 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.vhri.2014.06.001.
Both EQ-5D-5L and EQ-5D-3L value sets have the same range
(from 0.523 to 1.000), but different means (0.448 vs. 0.381) and
medians (0.483 vs. 0.406, respectively; Table 1). Sets differ in the
distribution of values. In general, the EQ-5D-3L value set has
proportionally more states worse than death (13.17% vs. 5.38%;
Fig. 1) and also more states of “good health” (9.05% vs. 5.15%
health states valued better than 0.8), whereas the EQ-5D-5L value
set characterizes with more states valued moderately. Fig. 2
presents a graphical comparison of both sets. Moving from “bad
health” to “good health” (from right side to left side on Fig. 2)
results in a smaller change in the EQ-5D-5L index value than in
the EQ-5D-3L index value.
Predicted Polish 5L values were compared with 3L values
observed in the subpopulation of Polish respondents from the
Crosswalk study (Table 2). Statistical measures of goodness of ﬁt
conﬁrmed good predictive power of the crosswalk mapping
algorithm for Polish respondents’ data.Discussion
We applied the crosswalk methodology developed by the EuroQol
Group to the existing Polish EQ-5D-3L value set, elicited with the
TTO method, to obtain an interim EQ-5D-5L value set. A number
of 3125 health state values are presented and ready for use in
economic and clinical analyses, based on the EQ-5D-5L, per-
formed in Poland.
The Polish EQ-5D-5L crosswalk value set is the ﬁrst and only
5L set in Central and Eastern Europe and as such may constitute
an option in countries of the region in which the reimbursement
Table 1 – Comparison of Polish EQ-5D-3L and Polish EQ-5D-5L crosswalk value sets.
Parameter Polish EQ-5D-5L
crosswalk value set
Polish EQ-5D-3L
value set
Number of health states 3125 243
Range 0.523 to 1.000 0.523 to 1.000
Mean  SD 0.448  0.254 0.381  0.310
Median (lower quartile – upper quartile) 0.483 (0.282 – 0.642) 0.406 (0.155 – 0.630)
Centile 5 – Centile 95 0.014 – 0.803 0.150 – 0.848
Skewness 0.542 0.347
States worse than dead (index o 0), n (%) 168 (5.38) 32 (13.17)
States with index 4 0.8, n (%) 161 (5.15) 22 (9.05)
EQ-5D-5L, ﬁve-level EuroQol ﬁve-dimensional; EQ-5D-3L, three-level EuroQol ﬁve-dimensional.
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5L crosswalk value sets are used worldwide in different clinical
populations [24–26].
We found that the Polish interim EQ-5D-5L value set generated
values that are to some extent more narrow than those generated
by the EQ-5D-3L TTO value set; that is, there are relatively less
health states valued “worse than death” or as good health (40.8)
and at the same time relatively more health states are valued
moderately (0.4–0.8). A similar relationship can be observed for
interim EQ-5D-5L value sets from other countries (Table 3). One of
the possible explanations is a restriction on the range of the scale.
A crosswalk method does not allow the value of 55555 to be lower
than that of 33333 (the range of index values is restricted to the
range of the EQ-5D-3L value set). Whether it is only the case of
crosswalk methodology, or may be, to some extent, characteristic
of the EQ-5D-5L, is unresolved at the moment.
This study helps users of the crosswalk for the EQ-5D-5L
understand the properties of the EQ-5D-5L values generated
using the crosswalk in comparison to values that would other-
wise be obtained using the EQ-5D-3L algorithm for the Polish
population. It is likely that similar results would be observed for
value sets in other countries because the same crosswalk meth-
odology applies across all countries.0%
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Fig. 1 – Histograms for Polish EQ-5D-3L and Polish EQ-5D-5L cro
dimensional; EQ-5D-3L, three-level EuroQol ﬁve-dimensional.There are limitations to the mapping approach, which is data
dependent and requires additional assumptions and introduces
additional errors. Although many approaches were explored by the
EuroQol research team that published the crosswalk algorithm [12],
it should be considered second best to direct utility measurement.
The crosswalk mapped between descriptive systems, which did not
allow the value set to address some of the limitations that a ﬁve-
level system could ameliorate in theory, such as extending the
continuum of the scale and reducing the gap in values between
health states with mild problems and no problems.Conclusions
A EQ-5D-5L value set was estimated using the crosswalk method-
ology, based on the Polish EQ-5D-3L values, and can now be
applied to studies using the EQ-5D-5L. It should be considered an
interim value set until supplanted by a value set for the EQ-5D-5L
that is derived from preferences elicited directly from a represen-
tative sample of the Polish general population. This study helps
users of the crosswalk algorithm understand the properties of the
EQ-5D-5L values generated using this method, in comparison to
EQ-5D-3L values obtained with the Polish TTO value set. It is likely0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95
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Fig. 2 – Graphical comparison of Polish EQ-5D-3L and Polish EQ-5D-5L crosswalk value sets (3L, black dots; 5L, gray line). EQ-
5D, EuroQol ﬁve-dimensional; EQ-5D-5L, ﬁve-level EuroQol ﬁve-dimensional; EQ-5D-3L, three-level EuroQol ﬁve-dimensional.
Table 2 – Mean observed EQ-5D-3L indexes (Polish TTO value set) and EQ-5D-5L indexes based on Polish
crosswalk value set in subpopulation of Polish respondents in the crossover study (n ¼ 972).
EQ-5D-5L
health state
n Mean observed
EQ-5D-3L value
SE EQ-5D-5L crosswalk
index value
MSE
11112 92 0.951 0.005 0.940 0.002
11113 16 0.928 0.008 0.925 0.001
11121 28 0.918 0.009 0.915 0.002
11122 63 0.896 0.006 0.887 0.003
11123 20 0.890 0.010 0.879 0.002
11222 24 0.844 0.008 0.848 0.002
21222 12 0.740 0.038 0.805 0.020
55533 12 0.090 0.000 0.090 0.000
55544 14 0.142 0.068 0.171 0.061
Note. Only health states with frequency 4 10 are presented.
EQ-5D-5L, ﬁve-level EuroQol ﬁve-dimensional; EQ-5D-3L, three-level EuroQol ﬁve-dimensional; MSE, mean squared error; SE, standard error.
Table 3 – Distribution of health state values in EQ-5D-5L crosswalk value sets and EQ-5D-3L TTO value sets in
10 countries.
Country % of states worse than dead (index o 0) % of states with index 4 0.8
5L crosswalk set 3L TTO set 5L crosswalk set 3L TTO set
Denmark 11.0 19.8 0.5 2.5
France 29.1 32.5 0.5 1.6
Germany 4.5 9.9 6.0 8.2
Japan 0.8 2.5 0.2 0.8
The Netherlands 9.5 14.8 1.2 4.5
Spain 27.9 37.4 1.1 4.1
Thailand 18.2 28.0 0 0
United Kingdom 26.7 34.6 0.6 2.5
United States 1.3 4.1 1.9 5.3
Zimbabwe 0.4 2.1 0.9 3.3
EQ-5D-5L, ﬁve-level EuroQol ﬁve-dimensional; EQ-5D-3L, three-level EuroQol ﬁve-dimensional; TTO, time trade-off.
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countries because the same crosswalk methodology applies across
all countries.
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